stockrowWhat it does
IQVIA is a global provider of clinical research services, commercial insights and healthcare intelligence for life-sciences and healthcare organizations. It was founded in 2016 and is headquartered in Danbury. Its work spans the path from designing and running clinical trials through helping customers understand treatment outcomes, satisfy regulatory requirements, plan product launches, and engage healthcare providers and patients.
The company combines healthcare data, technology, analytics and specialist services under IQVIA Connected Intelligence. Its information holdings include sales, prescription, claims, electronic medical-record and genomics data. IQVIA standardizes and connects those datasets so customers can analyze diseases, treatments, patient populations, commercial activity and clinical outcomes without using identified patient records.
Its clinical-research operations help biopharmaceutical companies plan studies, select sites, recruit patients, monitor trials, manage data, conduct laboratory testing and prepare evidence for regulatory submissions. Its commercial operations provide software, market information, consulting, sales-force support, patient-engagement programs and medical services. Customers also use its real-world evidence offerings to assess the safety, effectiveness and value of healthcare interventions after or alongside clinical development.
IQVIA has approximately 93,000 employees in over 100 countries, including healthcare, life-sciences, data-science, technology and operational specialists.
How it makes money
IQVIA earns service revenue rather than material product revenue. It sells hundreds of services, applications, technology platforms and solutions, often combining data, software, analytics and people around a customer’s clinical-development or commercial workflow.
During FY2025, its three reported segments were Research & Development Solutions, Technology & Analytics Solutions, and Contract Sales & Medical Solutions. Research & Development Solutions was the largest, at $8.9 billion of revenue and 54.5% of revenue. It provides outsourced clinical research, clinical-trial management and support, laboratories, strategic design, and patient- and site-centric services. Technology & Analytics Solutions generated $6.6 billion and 40.6% of revenue from information offerings, cloud applications, real-world evidence platforms, analytics and consulting. Contract Sales & Medical Solutions revenue increased from $718.0 million in FY2024 to $788.0 million in FY2025, and represented 4.83% of revenue in FY2025 through provider engagement, patient engagement and medical services.
Effective January 1, 2026, IQVIA changed its reportable segments to Commercial Solutions and Research & Development Solutions. Commercial Solutions incorporates the former Contract Sales & Medical Solutions business into the former Technology & Analytics Solutions commercial offerings. Certain Real-World Late Phase and other Real-World offerings moved to Research & Development Solutions.
Revenue is generated from service contracts, including clinical projects and technology-related engagements. Subscription-style information offerings and cloud-based applications can support recurring customer relationships, while clinical-trial work is project-based and can change with a customer’s development plans. The company reported approximately $34.2 billion of remaining performance obligations at December 31, 2025. It was reported on 22 October 2026 that the consensus Q3 2026 revenue estimate was $4.4 billion.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Research & Development Solutions | $8.9 billion | 54.5% | 4.33% |
| Technology & Analytics Solutions | $6.6 billion | 40.6% | 7.56% |
| Contract Sales & Medical Solutions | $788.0 million | 4.83% | 9.75% |
Customers and how it sells
Life-sciences companies account for the majority of IQVIA’s revenue. Its customers include pharmaceutical, biotechnology, device, diagnostic and consumer-health companies, as well as medical researchers, payers, providers, government and regulatory agencies, pharmaceutical distributors and pharmacies. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenue, are customers.
The company serves a diversified base of more than 10,000 clients in over 100 countries. No individual client accounted for 10% or more of total revenue in 2025, 2024 or 2023; the largest client represented approximately 5% of 2025 revenue. Customers can buy country-level and sub-national information offerings, cloud applications, consulting, outsourced clinical services, sales-force services and patient programs. Many large pharmaceutical customers subscribe to reports and services in multiple countries.
The Americas generated $7.7 billion, or 47.5%, of FY2025 revenue. Europe and Africa generated $5.2 billion, or 31.8%, and Asia-Pacific generated $3.4 billion, or 20.7%. IQVIA receives healthcare records and operates services across countries, while local regulations, customer requirements and healthcare systems affect how it manages data and delivers work.
| Region | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Americas | $7.7 billion | 47.5% | 5.29% |
| Europe and Africa | $5.2 billion | 31.8% | 5.39% |
| Asia-Pacific | $3.4 billion | 20.7% | 8.02% |
Suppliers and costs
IQVIA depends on third parties for data and support services. Its information assets are sourced from approximately 150,000 data suppliers and more than one million data feeds globally. The company receives healthcare records, processes them through its technology infrastructure, and applies privacy, security, contractual and legal protections before using non-identified information in its offerings.
As a services business, its principal costs are employee compensation and benefits, particularly for billable clinical, data-management, technology and delivery personnel. Cost of revenue also includes data acquisition and processing, technology-service delivery, trial-monitoring costs, investigator payments, clinical-monitor travel, courier fees, laboratory supplies and professional services. Selling, general and administrative expense includes sales, marketing, legal, finance, quality assurance, compliance, information technology and facilities.
IQVIA does not describe manufacturing operations. Its laboratory activities involve handling, testing, storage and transport of clinical specimens and are subject to applicable laboratory, safety and hazardous-material requirements.
- Revenue$16.3B
- Cost of revenue−$10.9B
- Selling, general and administrative−$2.0B
- Other operating costs−$1.2B
- Operating income$2.2B
Competitive position
IQVIA competes in healthcare information, analytics, technology, consulting, clinical research and contract commercial services. In Technology & Analytics Solutions, named competitors include Accenture, Aetion, Cognizant Technology Solutions, Deloitte, Oracle Health, Optum Insight, Medidata, Veeva and ZS Associates, alongside customers’ internal capabilities and organizations that provide their data directly to others. In clinical research, larger named competitors include ICON plc, Parexel International Corporation, Pharmaceutical Product Development, Inc., part of Thermo Fisher Scientific Inc., and Syneos Health. Contract sales and medical services compete with in-house commercial teams and providers including Syneos Health, Amplity Health, Eversana and Inizio.
Competition also comes from thousands of smaller limited-service clinical research organizations, regional providers, new entrants and start-ups. The company operates in markets where customers can consolidate vendors, build capabilities internally, or change technology providers.
Our reading: IQVIA’s data scale is a meaningful moat source because its offerings combine information from approximately 150,000 suppliers, extensive data feeds and longitudinal non-identified patient records; privacy and data-use rules make comparable collection and integration demanding.
Our reading: its global service network, broad clinical and commercial offerings, and relationships across more than 10,000 clients provide a meaningful scope advantage, though full-service global CROs, technology firms and internal customer teams remain established alternatives.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Accenture | healthcare information, analytics, technology and consulting | Medium |
| Aetion | healthcare analytics and real-world evidence | Medium |
| Cognizant Technology Solutions | technology, services and consulting | Medium |
| Oracle Health | healthcare technology and data services | Medium |
| Optum Insight | healthcare information and analytics | Medium |
| Medidata | clinical technology and data platforms | Medium |
| Veeva | life-sciences software applications | Medium |
| ICON plc | global clinical research services | High |
Growth opportunities
IQVIA’s growth strategy centers on connecting its healthcare information, analytics, technology and domain expertise across clinical development and commercialization. The company sizes its 2025 addressable market across outsourced research and development, real-world evidence and connected health, and technology-enabled commercial operations at approximately $335 billion.
It identifies demand from drug-development complexity, healthcare-data fragmentation, the need to demonstrate treatment value, and customer efforts to reduce costs and use variable-cost outsourcing. The company expects biopharmaceutical companies to use partners for clinical development and commercial operations as they seek efficiency, local expertise, patient recruitment, data integration and regulatory support. It also plans to expand services for payers, providers, healthcare professionals, governments and non-governmental organizations, and expects to consider acquisitions that extend its platform.
In FY2025, Research & Development Solutions revenue grew 4.33%, Technology & Analytics Solutions revenue grew 7.56%, and Contract Sales & Medical Solutions revenue grew 9.75%. The company says that RFP flows increased by strong double digits in Q2 2026 and that its win rate increased. It also says 19 of the top 20 pharmaceutical companies have deployed active IQVIA AI solutions in their workforce, and it expects broader use of AI capabilities across clinical and commercial work to generate incremental revenue.
- $13.9BFY2021
- $14.4BFY2022
- $15.0BFY2023
- $15.4BFY2024
- $16.3BFY2025
- $17.4BFY2026 guidance
Structural risks
-
Contract cancellations and delays. Research & Development Solutions clients can generally terminate contracts on 30 to 90 days’ notice. Trial decisions, financing, budget limits, regulatory actions, enrollment problems, safety or efficacy results, and shifts to competitors or internal resources can reduce or delay work.
-
Data, systems and cyber exposure. IQVIA depends on third parties for data and support services. Security breaches, cyberattacks, system failures or unauthorized use of its systems and information could expose the company, clients and data suppliers to losses and interrupt services.
-
Regulation and compliance. Clinical trials, laboratories, patient information, drug promotion and medical-device-related services are extensively regulated across jurisdictions. Non-compliance can result in trial termination, data disqualification, sanctions, fines or limits on operations.
-
Competitive and technological change. The biopharmaceutical-services industry is highly competitive. IQVIA competes with global and specialist service providers, technology firms, new entrants and customers’ internal capabilities, and must adapt to technological change.
-
International operations and currency. Approximately 30% of 2025 revenue was denominated in currencies other than the U.S. dollar. Political, economic, regulatory, payment, foreign-exchange and operational conditions across markets can affect reported results and service delivery.
-
Debt restrictions. Senior secured credit facilities and other indebtedness may limit the company’s ability to operate, finance capital needs or undertake other business activities.
Bottom line
Our reading
Our reading: IQVIA is a global, service-led healthcare infrastructure business whose revenue comes from clinical outsourcing and from data, technology and commercial services used by life-sciences customers. Its business rests on a large healthcare-information network, specialist workforce and multi-country delivery capabilities. Its exposure is to clinical-development budgets, contract timing, third-party data, regulation, cyber security, foreign operations and substantial competition from CROs, technology providers and customer in-house teams.